Eyeworld Daily News

39 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 BARCELONA, SPAIN JUNE 16–19, 2018 | B A R C E L O N A | J U N E 1 6 – 1 9 | B A R C E L O N A | J U N E 1 6 – 1 9 SIGN UP FOR WOC2018 UPDATES! WWW.ICOPH.ORG/WOC2018 PARTICIPATE in cutting-edge continuing education opportunities. NETWORK with more than 10,000 attendees from over 120 countries. VISIT more than 100 exhibiting companies. ATTEND hundreds of scientific sessions led by renowned experts. Host: Spanish Society of Ophthalmology Co-Hosts: European Society of Ophthalmology and Spanish Society of Implant-Refractive Ocular Surgery continued from page 38 In the 2015 ASCRS Clinical Sur- vey, 8% of surgeons said they were using presbyopia-correcting IOLs with patients, but 12% said they intended to use them with patients in the next 3 years. When surgeons had used presbyopia-correcting IOLs, 90% said their patients were happy with their near vision, and 92% were happy with their distance vision, reported Bonnie Henderson, MD, Boston, during the session. "We fear these lenses, but the patient outcomes are excellent," she said. One key part of working with presbyopic correction is patient education, said Daniel Durrie, MD, Overland Park, Kansas. Dr. Durrie explains to patients the 3 stages of the dysfunctional lens syndrome (DLS), and he uses videos, oral explanations, and even eye models to make his point. He lets patients know that in their 40s, in stage 1, they are starting to lose some of the "zoom" out of their vision, likening it to a camera. In their 50s—stage 2—night vision usually becomes worse, and they need more light to read. Stage 3 is the development of a cataract. Dr. Durrie will explain treatment options available at each stage. Although patients in the early stages do not always want a surgical treatment, he thinks that will be more common going forward. "Explaining DLS is easy, and patients appreciate it," Dr. Durrie said. Make sure that your staff is well educated on DLS so they also can explain it. Much of a practice's work with presbyopic patients will center around setting realistic expectations, said John Vukich, MD, Madison, Wisconsin. As physicians become more involved in presbyopic treatment choices—be it monovision, corneal inlays, or premium IOLs—they will have to increasingly consider patient lifestyles and desires. "You have to know their lifestyle, personality, de- gree of astigmatism, and preexisting conditions [that could be a contrain- dication]," she said. Dr. Donaldson uses a questionnaire that patients fill out before they see her so she can save time and consider best choices for patients. She also relies on physician extenders to help with patient education and information gathering. Dr. Donaldson is cautious about not treating patients who may feel there's not a true benefit from treat- ment—for example, a –2 D myope. Daniel Chang, MD, Bakersfield, California, discussed the balance of vision quality, depth of field, and night vision symptoms that presby- opia-correcting solutions are aiming to achieve. While there is typically a compromise in one of these areas when there's a gain in the other ar- eas, treatment options are becoming increasingly better, he said. As presbyopic treatment be- comes more of a norm, Dr. Durrie sees a change not only among patients but also among surgeons, who have told him they want to be a "presbyopic surgeon" instead of saying they want to be a "LASIK surgeon," which was more common in the past. EW Editors' note: This event was support- ed by educational grants from Abbott Medical Optics (Abbott Park, Illinois), AcuFocus (Irvine, California), Alcon (Fort Worth, Texas), and Bausch + Lomb (Bridgewater, New Jersey).

• Cover